Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Core Viewpoint - Corvus Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 7,900,677 shares at a price of $22.15 per share, aiming to raise approximately $175.0 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,185,101 shares at the public offering price [1]. - The expected closing date for the offering is around January 23, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, which may encompass capital expenditures and research and development for various clinical trials, including Phase 3 T cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma [2]. Group 3: Underwriters - Jefferies and Goldman Sachs & Co. LLC are serving as lead book-running managers for the offering, with Mizuho as the bookrunner and Ladenburg Thalmann & Co. Inc. as a co-manager [3]. Group 4: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various immune diseases and cancers. The lead product candidate is soquelitinib, currently in a Phase 3 trial for relapsed/refractory PTCL and a Phase 1 trial for atopic dermatitis [6].